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Erectile dysfunction is a common complaint after the age of 40. It is rampant in this era 
of early onset hypertension and diabetes where in even people younger than 30 years 
commonly encounter the problem. The problem often goes under noticed because of the 
emotional aspect it has and the social stigma that has been attached with it. This fact is 
supported by the truth that  the exact  incidence of erectile  dysfunction in developing 
countries like India is still unknown. Even then the number of cases presenting to the out 
patient department is going on increasing insisting the magnitude of the problem as well 
as the people’s awareness.
Since erection involves a complex physiology, it goes with out saying that the 
causative factors involved in the erectile dysfunction are diverse. One traditional way of 
classification  is  in  to  three  types,  namely  psychogenic,  organic  and mixed.  Organic 
causes include neurogenic, hormonal, arterial, cavernosal and drug-induced. Identifying 
exact etiology becomes very essential because certain conditions could be treated and 
reversible if not completely.
Penile Doppler plays a pivotal role in the investigation process of a patient with 
erectile  dysfunction.  It  is  often  the  commonly  employed  modality  after  clinical 
examination  and basic  blood chemistry  is  obtained.  It  rules  out  arterial  and venous 
causes of erectile dysfunction and local cavernosal pathologies. Routine method is to 
produce a pharmaco erection and studying the cavernosal arteries’ Doppler wave form. 
Conventionally Papaverine is used as an intra cavernosal injection to induce erection. 
Though till date Papaverine is the most potent erectogenic drug available in the market, 
it  is  invasive and produces side effects.  Intra cavernosal  injection is associated with 
anxiety which can dangerously affect the patient’s erectile performance.
In  the  quest  of  an  alternative  to  Papaverine  we  have  tried  Tab.Sildenafil  in 
performing penile Doppler as an erectogenic drug. 
Aims and objectives:
• To prospectively evaluate the efficacy of Tab.Sildenafil in doing penile Doppler 
• To compare Tab.Sildenafil with Inj.Papaverine in penile Doppler  study in terms 
of clinical and hemodynamic parameters 
Review of literature:
There are about three clinical studies which has compared Sildenafil and Papaverine in 
doing penile Doppler. 
Study by Aslant et al1 at Firat university school of medicine, Turkey was the first 
one to compare the efficiency of oral phosphodiesterase inhibitors with intra cavernosal 
injection of vaso active agents.  The drawback of the study was lack of concomitant 
Doppler and clinical assessment of erectile function.
Speel TG et al2 did works to assess whether a single intracavernous injection (ICI) 
of a low dose of the combination of papaverine-phentolamine is replaceable by a high 
dose of the oral erectogenic agent sildenafil as mode of stimulation during pharmaco-
penile  duplex  ultrasonography.  He  concluded  that  as  mode  of  stimulation  in  penile 
duplex sonography, high dose sildenafil yields significantly less false positive diagnoses 
of  'veno-occlusive  dysfunction'  than  intracavernous  injection  of  the  combination 
papaverine/phentolamine. No difference was found in the quality of the arterial response
Copel  et  al3  tested  the  efficacy  of  Sildenafil  with  and  without  audio  visual 
stimulation  comparing  to  Inj.Papaverine.  The  study  concluded  that  there  was  a 
significant increase in blood in the penile vasculature after ingestion of Sildenafil with 
audiovisual stimulation. But the response is clinically and hemodynamically inferior to 
that with intra cavernosal vaso active agents. The study design contained a small number 
of sample size (thirteen subjects) and was liable to bias. 
Our present study is unique in that it  includes a large number of sample sizes 
which necessarily rules out the possibility of statistical bias. It is also very special in that 
it incorporates both clinical and Doppler hemodynamic response after each drug trial. 
Thus  we  were  able  to  get  a  comprehensive  assessment  of  a  patient  with  erectile 
dysfunction.
Physiology of Erection
Penile  erection  is  primarily  a  neurovascular  event  modulated  by  psychological  and 
hormonal  status.  Sexual  stimulation  causes  a  release  of  neurotransmitters  from  the 
cavernous nerve terminals and relaxing factors from the endothelial cells in the penis, 
resulting in  relaxation of  smooth muscle  in  the arteries  and arterioles  supplying the 
erectile tissue.
Vascular Events:
A  several-fold  increase  in  blood  flow  occurs  with  a  concomitant  increase  in 
compliance of the sinusoids from relaxed cavernous smooth muscle, facilitating rapid 
filling  and  expansion  of  the  sinusoidal  system  against  the  tunica  albuginea.  The 
subtunical venular plexuses are thus compressed between the trabeculae and the tunica 
albuginea,  resulting in almost  complete occlusion of venous outflow (Fournier et  al. 
19874; Banya5 et al. 1989). Blood is trapped within the corpora cavernosa, which raises 
the  flaccid  penis  to  an  erect  state.  Intracavernous  pressures  are  increased  to 
approximately  100  mmHg  (the  full  erection  phase).  During  sexual  activity,  the 
bulbocavernosus  reflex  is  triggered,  thus  causing  the  ischiocavernosus  muscles  to 
forcefully compress the base of the blood filled corpora cavernosa and the penis. The 
penis becomes very rigid, with an intra cavernous pressure reaching several hundred 
mmHg (the rigid erection phase).  During this phase,  inflow and outflow temporarily 
cease. Detumescence can be the result of three separate activities: sympathetic discharge 
during  ejaculation,  breakdown  of  second  messengers  by  phosphodiesterases,  or 
cessation  of  erectile  neurotransmitter  release.  The  venous  channels  open  with 
contraction of the trabecular smooth muscle, therefore expelling the trapped blood and 
restoring flaccidity. 
Nervous Events:
The penis is innervated by autonomic and somatic nerves. The somatic component is 
controlled by  the  pudendal  nerve,  which is  responsible  for  penile  sensation  and the 
contraction  and  relaxation  of  the  bulbocavernosus  and  ischiocavernosus  striated 
muscles. Blood flow during erection and detumescence is regulated via the cavernous 
nerves,  consisting of  sympathetic  and parasympathetic  nerve fibers,  which merge to 
form these nerves in the pelvis.  The principal  neurotransmitter for  penile erection is 
nitric oxide, which is released from non adrenergic-noncholinergic neurotransmission of 
the cavernous nerves and the endothelium (Lue 20006). Nitric oxide activates soluble 
guanylyl cyclase raising intracellular concentrations of cyclic guanosine monophosphate 
(cGMP). cGMP in turn activates a cGMP-specifi c protein kinase, which phosphorylates 
certain proteins and ion channels, resulting in opening of the potassium channels and 
hyperpolarization, sequestration of intracellular calcium by the endoplasmic reticulum, 
and inhibition of calcium channels, blocking calcium influx. The consequence is a drop 
in cytosolic calcium and smooth muscle relaxation/erection. During the return to the 
flaccid state, cGMP is hydrolyzed to guanosine monophosphate by phosphodiesterase 
type 5. Other phosphodiesterases are also found in the corpus cavernosum, but they do 
not appear to play an important role in detumescence.
Performing a penile Color Doppler Ultrasonography
Ultrasonography:
Ultrasound evaluation of patients with erectile dysfunction should be performed in the 
appropriate environment, respecting the privacy of the patient. Good quality equipment 
and transducers suited to evaluation of superficial structures must be used. 
Environment:
The  sonographic  examination  of  the  patient  with  erectile  dysfunction  cannot  be 
considered  corresponding  to  a  conventional  ultrasound  scanning,  but  requires  some 
basic rules of privacy, avoiding all the negative factors depending on the environment, 
which can interfere dangerously with the erectile phenomenon (Broderick 19987). An 
independent  and  dedicated  ultrasound  laboratory  supplied  with  the  technical 
requirements that can amplify or improve the action of the drugs used to induce the 
erection  is  desirable,  even  if  not  mandatory.  In  any  case  the  laboratory  where  the 
examination is performed must be locked, and nobody should be allowed to enter during 
the examination time. Low lighting is preferable and the presence of a maximum of two 
medical staff. Avoiding the presence of nurses is recommended with the exclusion of the 
preliminary phases to reduce the negative influence of psychological factors. After the 
intracavernosal  drug  injection,  the  patients  can  be  left  alone  before  the  Doppler 
measurements on both cavernosal arteries are performed. Once the evaluated parameters 
become stable, but the erection obtained is insufficient or absent, the patient is usually 
left alone for some minutes and invited to stimulate the penis manually. If the degree of 
the rigidity obtained is less than the best spontaneous erection referred by the patient 
during normal sexual activity, a second dose of prostaglandin can be injected. When a 
venous erectile dysfunction is suspected, it is useful to ask the patient to stand and invite 
him to walk, because this will increase the erection and reduce the examination time. 
The increased erection obtained is psychologically important for the patient. To improve 
the drug response, audiovisual sexual stimulation has been proposed to promote smooth 
muscle relaxation during penile color Doppler examination. Audiovisual stimulation is 
performed with commercially available virtual glasses with tridimensional capabilities 
and stereophonic  headphones.  The  device  allows the  patient  to  be  cut  off  from the 
surrounding environment without increasing test-related stress and anxiety. This type of 
induced arousal suggests the possibility of performing the dynamic evaluation with a 
reduced dose of the drug or with simple oral agents in place of intracavernosal injection 
(Pescatori8 et al. 2000; Park9 et al. 2002). The clinical results are suggestive, but the 
method is not in very widespread use and needs more extensive confirmation. 
Transducers:
High frequency  small  parts  transducers  are  mandatory,  preferably  with  high  density 
crystals so that an elevated spatial resolution is possible both at grey-scale and color-
Doppler ultrasound. Gain and power settings should be optimized so that all structures 
of the penis are appreciable. Harmonic imaging and 3D reconstruction techniques can be 
used, if available, but they are not mandatory for the diagnosis even though they can 
offer a more detailed image of the small post-cavernosal arteries, which are frequently 
compromised in subjects with diabetes or systemic arterial disease.
Vasoactive Drug Delivery:
A variety of techniques have been suggested for delivery of vasoactive drugs in patients 
with  erectile  dysfunction  undergoing  color  Doppler  evaluation.  While  the  most 
commonly  used  method  is  intracavernosal  injection,  other  modalities  such  as 
transurethral  and transdermal  drug delivery  have  been considered,  in  the  attempt  to 
reduce the invasive character of the study, and risk of possible complications. 
Intracavernosal Injection:
Intracavernosal injection of vasoactive substances (dynamic penile ultrasonography) is 
one  of  the  most  important  phases  in  the  examination  of  patients  with  erectile 
dysfunction.  This  minimally  invasive  procedure  is  associated  with  anxiety  and 
apprehension  that  may  negatively  influence  the  erectile  response  and  cause  false-
positive results. The substances used in the clinical practice vary in composition, dose 
and  mechanism  of  action  (Meuleman10 et  al.  1992).  Sometimes  they  can  be  used 
simultaneously in the same mixture. Currently, the most diffuse product is prostaglandin 
E1 (PGE1), which is used at doses varying from 5 mcg to 20 mcg. It is a product with a 
high level of security and safety, because it seldom induces a persistent priapism that 
requires medical or surgical interventions. The employed dose is selected on the basis of 
the preliminary clinical assessment, which allows the patients to be divided into two 
main groups. The first includes subjects who still have nocturnal erections and some 
preserved sexual activity; in this group a single dose of 5 or 10 mcg can be sufficient, 
but, if an incomplete erection is obtained, a second injection can be performed after 30 
min to differentiate a real organic erectile dysfunction from an insufficient response to a 
low dose of  the drug (Lehmann11 et  al.  1999;  Chen et  al.  2000).  The second group 
includes those who report short erections, generally insufficient to perform a complete 
intercourse. In this case a 20-mcg dose of PGE1 is preferred (Lehmann11 et al. 1999). 
Prostaglandins can be responsible for a longstanding erection that lasts 3–4 h associated 
with pain, which generally disappears spontaneously probably as a consequence of the 
complete  metabolic  consumption  by  the  intracavernosal  enzymes.  Papaverine  is  the 
second most used drug to stimulate erections at a dose ranging from 10 to 40 mg. A 
great individual variability in the response to the same dose has been observed and the 
time of erection is usually longer than that obtained with PGE1 (Fitzgerald12 et al. 1991). 
The  most  common systemic  signs  are  secondary  to  peripheral  vasodilatation  with  a 
sense of heat and occasionally hypotension. These effects are sometimes not tolerated by 
the patients performing self-injection at home. Focal fibrosis of the erectile tissue or 
diffuse corporeal fibrosis have been frequently  observed and are the consequence of 
focal or diffuse ischemia of the erectile tissue. For these reasons papaverine is currently 
not used systematically even though its erectile effect is more intense and the rigidity 
more evident than with other vasoactive products. The relaxation of the erectile tissue 
and the vasodilatation obtained with papaverine are generally more evident, probably 
because of the higher quantity of nitric oxide (NO) involved. The action of the NO is 
essentially an arterial vasodilatation, while the effect on the cavernosal musculature is 
less  evident.  Other  drugs  used  are  phentolamine  and phenoxybenzamine,  alpha-lytic 
drugs that produce relaxation of the smooth muscle of the arterial wall and of the erectile 
tissue.  Some  authors  have  proposed  the  use  of  a  mixture  of  all  three  vasoactive 
substances, whose action is similar, but probably follow different biochemical pathways: 
papaverine, phentolamine and prostaglandin. The erectile response observed in patients 
without arteriogenic erectile dysfunction is usually intense and the incidence of priapism 
frequent. The association called “Trimix” shows a high incidence of complications, and 
the individual dose is difficult to define. The intracavernosal injection is performed on 
the lateral aspect of the penis at the proximal or medial third of the shaft. Commonly, a 
30-G needle is used and the puncture is performed away from the dorsal nerves of the 
penis. Intraspongiosal or intraurethral injection should be carefully avoided. Incorrect 
puncture can produce pain, particularly if performed near the dorsal nerves, or urethral 
pain/heat, if the product has been injected into the corpus spongiosum. Subcutaneous 
injections cause less pain and local swelling, but no erection. These complications are 
more  frequently  observed  in  patients  at  the  beginning  of  self-injection. 
Schematic drawing showing the elective site on the lateral surface of the penis (*) where 
to perform intracavernosal drug injection
Scanning:
Ultrasound examination of the penis in patients with erectile dysfunction is performed 
with scans at rest, before induced erection and in the erection/tumescence phases. After 
intracorporal drug injection scans are usually performed after 5, 10, 15 and 20 min at the 
level of both cavernosal arteries. Scanning is preferably made on the ventral surface, 
especially when the erection is obtained, because the probe orientation is particularly 
favorable to study the cavernosal flow. The basal study generally has a low diagnostic 
yield and can be omitted if a preliminary clinical evaluation has been performed. After 
drug injection grey-scale  scanning is  performed that  allows a  good detection  of  the 
cavernosal arteries and evaluation of the cavernosal tissue distension. The septum and 
the tunica albuginea are well depicted. Afterwards color imaging is performed using a 
reduced field of view to maintain a high frame rate. Pulse repetition frequency (PRF) 
values of 1,000– 1,500 Hz are employed with a low wall filter. Longitudinal scans on 
the  cavernosal  arteries  are  performed with steering  of  the color  box so  that  a  good 
definition of the blood flow is acquired. The cavernosal arteries have a parallel course to 
the linear probe with a non-favorable Doppler angle, because of being perpendicular to 
the  direction  of  flow.  The  sample  volume  size  is  about  1  mm,  which  is  the 
corresponding measure of the diameter of the cavernosal vessels. Color imaging allows 
an easy detection of the arteries from the base of the penis down to the retrobalanic 
zone.  Anatomical  variations of  the cavernosal  arteries  are  present  in 20–30% of the 
patients with double or triple arterial vessels. They can have the same outer diameter or 
can be different in size and length. The blood velocities measured are dependent of their 
diameter (Mancini13 et al. 1996). The helicine arterioles and their branches can be easily 
detected  because  of  their  perpendicular  course  in  respect  to  the  probe.  The  3D 
reconstruction of the intracorporeal vessels allows defining the spatial distribution of the 
small vessels and a semi quantitative evaluation of the vascular density and of the size of 
the helicine arterioles, which are frequently compromised in patients with diabetes or 
systemic vascular pathology. Following identification at color Doppler ultrasound, the 
cavernosal  vessels  are  interrogated.  Pulse-wave  (PW)  duplex  Doppler  is  turned  on 
putting the sample volume on the cavernosal arteries. The spectral analysis is preferably 
performed at the base of the penis where the Doppler angle is particularly favorable 
(between  30°  and  50°)  and  the  flow  velocity  shows  major  reproducibility  and 
correctness (Mills14 and Sethia 1996). The flow velocity must be measured repeatedly (at 
least three times) at the same level and the mean value reported. Functional studies have 
shown a progressive decrease of blood velocity in the cavernosal arteries from the base 
to the glans penis. 
Timing:
The time necessary to obtain an erection after pharmacostimulation varies greatly from 
one patient to another. For this reason continuous monitoring is necessary up to 30–40 
min. In some subjects a rapid erection is observed after 5 min, but in the majority of the 
examinations it is necessary to wait 15–20 min to have a stable erection. If the erection 
does not realize after 20 min, it is good practice to prolong the test to 30–40 min to 
exclude late responses. To reduce the time to erection the patient can be invited to stand 
up and to walk in the ultrasound laboratory. Sexual visual stimulation can be employed 
with  good results  (Erbagci15 et  al.  2002).  All  these  maneuvers  increase  the  erection 
firmness  especially  in  patients  with  venous  leakage  because  of  the  increase  of  the 
venous pressure in the superficial and deep venous network of the penis (Pescatori et al. 
2000; Park et al. 2002).
The introduction of phosphodiesterase-5 (PDE5) inhibitors has revolutionized the 
therapy of  erectile  dysfunction and radically  changed the way in  which patients  are 
investigated (Speel2 et al. 2001). Documentation of a good quality erection in response 
to a PDE5-inhibiting drug confirms grossly adequate arterial inflow and effective veno 
occlusive mechanisms. However, Doppler interrogation of penile vessels continues to 
have a role in the evaluation of specific patients presenting with erectile dysfunction, in 
particular, in trauma patients and in patients with Peyronie’s disease.
Sonographic anatomy and hemodynamics of penile vasculature 
Grey-Scale Ultrasound Anatomy:
The different anatomical features of the penis are better evaluated during tumescence 
and erection  (Lue62 et  al.  1985).  In  the  flaccid  state,  the  corporal  bodies  present  at 
ultrasonography  as  cylindrical  structures  with  intermediate  echogenicity  and 
homogeneous echotexture. The corpus spongiosum and the glans are more echogenic 
than the corpora cavernosa. When collapsed, the urethra appears as a transverse line. 
The echogenicity of the corpora cavernosa progressively decreases during tumescence 
starting  from  the  region  surrounding  the  cavernosal  arteries  because  of  sinusoids 
dilatation. During maximal penile rigidity, a fine echogenic network is appreciable in the 
corpora cavernosa due to sinusoidal interfaces. Sinusoidal spaces at the base of the penis 
are normally larger that in the remaining portions of the shaft. Blood entrapped within 
the sinusoids often appears slightly corpusculated. The Colles’ fascia is barely visible in 
normal  patients.  The  tunica  albuginea  and the  Buck’s  fascia  are  stuck  together  and 
appear as a thin echogenic line surrounding the corpora, which became thinner during 
erection.  Two  distinct  layers  become  appreciable  only  when  fluid  extravasation 
accumulates  between  them  or  very  high  frequency  transducers  are  used.  Vascular 
structures, however, may provide a suitable interface to separate small portions of the 
Buck’s  fascia  from  the  underlying  tunica  albuginea  in  normal  penises  as  well.  In 
particular, the Buck’s fascia becomes visible at ultrasound near dilated circumflex veins, 
and a subtle echogenic line representing the Buck’s fascia is usually recognized in the 
dorsal  aspect  of  the  penis  dividing  the  plane  of  the  deep  vessels  from that  of  the 
superficial  vessels  (Lue62 and Tanagho  1987;  Mueller  and Lue 1988)  and near  the 
corpus spongiosum. The penile septum appears  as  an echogenic  structure  with back 
attenuation dividing the corpora cavernosa that can hamper visualization of the tunica 
albuginea in the dorsal aspect of the penis. The intracavernous pillars are recognizable 
on transverse scans as straight echogenic lines thicker than the sinusoidal walls, which 
run from one side to the other of the tunica albuginea. The distal penile ligament, an 
aggregation of the outer longitudinal layer of the tunica albuginea that acts as a buttress 
for the glans penis (Hsu42 et al. 2004; Hsu et al. 2005), is recognized at ultrasound as a 
linear structure more echogenic than the surrounding glanular tissue located centrally 
within the glans dorsal to the distal urethra. Several penile vessels can be identified at 
grey scale ultrasound as well. In particular, the cavernosal arteries appear as a pair of 
dots located slightly medially in each corpus cavernosum. On longitudinal scans they 
present  as  narrow tubular  structures  with  echogenic  wall  (Quam41 et  al.  1989).  The 
diameter of the normal cavernosal arteries ranges from 0.3 to 05 mm in the flaccid state 
and increases to 0.6–1.0 mm after  an intracavernosal  injection of  vasoactive agents. 
During the onset of erection, cavernosal artery pulsation is evident in normal subjects 
(Lee42 et al. 1993; Kim 2002). The dorsal arteries are visible in the dorsal aspect of the 
shaft as anechoic structures with a similar diameter to the cavernosal arteries. As occurs 
for  the  cavernosal  arteries,  also  the  diameter  of  the  dorsal  arteries  increases  during 
erection, but to a lesser extent compared with the cavernosal arteries (Lee et al. 1993). 
Dorsal veins present with less echogenic wall compared to the arteries. 
Duplex Doppler Interrogation:
Different Doppler waveforms are recognized in the cavernosal arteries while flaccid and 
during erection (Fitzgerald12 et al. 1991; Schwartz et al. 1991; Kim 2002). Peak systolic 
velocity  varies  significantly  according to  the  sampling  location.  In  general,  velocity 
values  are  highest  at  proximal  sites  and  decrease  progressively  at  distal  sites  of 
measurement (Chiou50 et al. 1999). As a consequence, standardization of the sampling 
location  is  needed  to  reduce  the  variability  of  duplex  Doppler  interrogation  of  the 
cavernosal  arteries,  which  is  performed  at  the  origin,  where  they  angle  posteriorly 
toward the crus, and a favourable Doppler angle is obtained (Kim57 2002).
Cavernosal Arteries:
These vessels  present  during the onset  of  erection with characteristic  progression of 
Doppler  waveform  reflecting  blood  pressure  changes  within  the  cavernosal  bodies. 
Spectral  waveform changes have been classified into six  phases scored from 0 to  5 
(Schwartz  et  al.  1991).  In  the  flaccid  state  (phase  0)  monophasic  waveforms  are 
recognized in the cavernosal arteries with low velocity, high resistance flow, typically of 
15–25 cm/s. With the onset of erection (phase 1), there is an increase in systolic and 
diastolic  flows.  Peak  systolic  velocity  >35  cm/s  and  diastolic  velocity  >8  cm/s  are 
usually recorded in normal subjects in this phase. Peak systolic velocities as high as 80–
100 cm/s and diastolic velocities of 20 cm/s or more are often recorded in young patients 
with normal erections. When the blood pressure within the corpora cavernosa begins to 
rise, a dicrotic notch appears at end systole, and a progressive decrease of the diastolic 
flow is observed (phase 2). When the cavernosal pressure equals the diastolic pressure, 
diastolic flow declines to zero. Holodiastolic flow reversal (phase 4) reflects cavernosal 
pressure above the diastolic pressure and full erection. During rigid erection the systolic 
envelope is narrowed and diastolic flow disappears (phase 5). The systolic peak reduces 
or  even  disappears,  reflecting  cavernosal  pressure  approaching  or  exceeding  blood 
systolic  pressure.  Cavernosal  phase  5  requires  contraction  of  the  bulbocavernous 
muscles and is not commonly observed after pharmacologically induced erection. The 
bulbocavernous reflex, however, can be stimulated with compression of the glans penis 
(Broderick and Arger 1993). During detumescence diastolic flow appears again. 
Normal waveform changes in the cavernosal arteries during the onset of erection. 
a Phase 0. Monophasic flow with minimal or no diastolic flow occurring in the flaccid 
state 
a.
b Phase1. Increased systolic and diastolic flow.
b.
c Phase 2.  Dicrotic notch appearance at end systole and progressive decrease of the 
diastolic flow. 
c.
d Phase 3. End diastolic flow disappearance
d.
e Phase 4. Diastolic flow reversal. 
e.
f Phase 5. Reduction of the systolic peak during rigid erection
f.
Dorsal Arteries:
These vessels are outside the tunica albuginea and therefore are not subjected to the 
intracorporeal pressure changes with each phase of erection; therefore, even in well-
sustained  rigidity,  anterograde  diastolic  flow  persists  (Broderick  and  Arger  1993). 
Generally speaking, Doppler spectral pattern and peak systolic velocity of dorsal penile 
arteries increase from about 20 cm/s while flaccid to 40 cm/s or more during erection 
(Lee et al. 1993).
Arterial Communications:
Doppler  waveform  changes  of  anastomotic  arterial  branches,  dorsal-cavernous  and 
cavernous-cavernous arterial communications are quite variable, depending on size and 
position along the shaft.
Cavernosal-Spongiosal Communications:
Also in these vessels characteristic changes are recognized reflecting waveform changes 
within the cavernosal arteries (Bertolotto et al. 2002). In particular, within the corpus 
cavernosum cavernosal spongiosal communications have arterial waveforms, and peak 
systolic velocity increases from approximately 6 cm/s while flaccid to approximately 10 
cm/s during erection. The resistive index progressively increases from cavernosal phase 
1 to phase 3. When full erection is reached cavernosal-spongiosal communications tend 
to close and disappear or, in other cases, their diastolic velocity markedly reduces or 
declines  to  0.  A characteristic  Doppler  spectrum can be appreciable  with  a  positive 
diastolic flow, which can be due to a steel phenomenon towards the corpus spongiosum 
and an inverse systolic peak that is likely due to the hydraulic “ram stroke” produced 
near the occlusion site.
Clinical and Doppler evaluation of erectile dysfunction
Classification and Epidemiology:
Erectile dysfunction may be classified as psychogenic, organic (neurogenic, hormonal, 
arterial, cavernosal and drug-induced), and mixed. Mixed erectile dysfunction is most 
commonly  encountered  having  both  a  psychogenic  and  organic  component.  Several 
pathophysiologic states, such as diabetes mellitus, may have detrimental effects upon 
erectile capacity via multiple pathways. Many epidemiologic studies have described the 
relationship between erectile dysfunction and increasing age, with a reported prevalence 
of 40% at age 40, compared to 70% by 70 years of age; for severe erectile dysfunction, 
rates triple from 5% to 15% for men aged 40 compared to 70 (Feldman et al. 19944). 
Longitudinal studies within a large cohort demonstrate a non-linear decline for  most 
aspects of sexual function as age increases, with a more pronounced decline in older 
groups  (Araujo  et  al.  200416).  As  the  latent  period  between  sexual  stimulation  and 
erection  increases,  erections  are  less  turgid,  ejaculation  is  less  forceful,  ejaculatory 
volume decreases, and the refractory period between erections lengthens. There is also a 
decrease in  penile  sensitivity  to  tactile  stimulation,  a  decrease in  serum testosterone 
concentration, and an increase in cavernous muscle tone (Kaiser et al. 198817; Rowland 
et al. 1989; Christ et al. 199018). While relational, psychological, and organic issues are 
important contributors to erectile dysfunction across age groups, organic issues tend to 
play a more pronounced role as men age (Corona et al. 200419).
Pathophysiology:
Although psychogenic erectile dysfunction was historically considered to be the most 
common cause,  mixed disorders are most common. Psychogenic erectile  dysfunction 
can  be  caused  by  performance  anxiety,  strained  interpersonal  relationships,  lack  of 
sexual  arousability,  and  overt  psychiatric  disorders  such  as  depression  and 
schizophrenia.  Several  studies  have  confirmed  the  strong  relationship  between 
depression and sexual dysfunction (Araujo et al. 199820; Shabsigh et al. 199821). Erectile 
dysfunction is noted in patients  with neurological  disorders such as Parkinson’s and 
Alzheimer’s  diseases,  stroke,  and  cerebral  trauma,  often  secondary  to  a  decrease  in 
libido or inability to initiate the erectile process. Spinal cord injury patients have varying 
degrees  of  erectile  dysfunction  largely  dependent  on  the  location  and  extent  of  the 
lesion. Sensory input from the genitalia is essential to achieve and maintain reflexogenic 
erection, and this input becomes more important as the effect of psychological stimuli 
abates with age. Other common causes of neurogenic erectile dysfunction are surgeries 
that affect the cavernous nerves, such as radical prostatectomy. Androgen deficiency 
results in a decrease in both nocturnal erections and libido. Although testosterone levels 
do not  correspond to severity of erectile  dysfunction,  in those patients with reduced 
libido there are lower levels of testosterone as compared to other patients (Corona et al. 
2004). However, erection in response to visual sexual stimulation is preserved in men 
with hypogonadism, suggesting that androgen is not absolutely essential for erections, 
due to multiple pathways (Bancroft and Wu 198322;  Angulo et al. 2005). Due to the 
inhibitory action of prolactin on central dopaminergic activity and the resultant decrease 
in gonadotropin-releasing hormone secretion, hyperprolactinemia of any cause results in 
both  reproductive  and  sexual  dysfunction  (via  secondary  hypogonadotropic 
hypogonadism).  Vascular  pathology  may  involve  lesions  of  the  inflow  or  outflow 
mechanisms  of  penile  erection.  Erectile  dysfunction  may  be  a  manifestation  of 
generalized  atherosclerosis  and  may  even  be  its  initial  presentation.  Common  risk 
factors associated with generalized penile arterial  insufficiency include hypertension, 
hyperlipidemia, cigarette smoking, diabetes mellitus,  and pelvic irradiation (Rosen et 
al.199123). Less commonly, local stenosis of the common penile artery may occur in 
men  who  have  sustained  blunt  pelvic  or  perineal  trauma  (Levine  et  al.  199024). 
Dysfunction  of  the  venoocclusive  mechanism  that  normally  allows  maintenance  of 
erection can cause erectile dysfunction (Rajfer et al. 198825) and may be the result of 
degenerative changes affecting the penis such as general aging, Peyronie’s disease, and 
diabetes mellitus. Peyronie’s disease is more common in middle age, but may be present 
in the aging male although it tends to be underdiagnosed, especially if there has been a 
long period without rigid erection. Although generally caused by global penile tissue 
degeneration, venoocclusive dysfunction may also be the result of congenital or trauma 
induced formation of large venous channels draining the corpora cavernosa. Venous leak 
can be seen in anxious men with excessive adrenergic tone causing structural alterations 
of the cavernous smooth muscle and endothelium and insufficient  trabecular smooth 
muscle relaxation (Christ et al.199026).Finally, venous leak can be seen in patients with 
acquired  shunts  that  result  from the  operative  correction  of  priapism.  A  variety  of 
commonly used medication7 have been reported to cause erectile dysfunction. Central 
neurotransmitter  pathways,  including  serotonergic,  noradrenergic,  and  dopaminergic 
pathways  involved  in  sexual  function,  may  be  disturbed  by  antipsychotics, 
antidepressants, and antihypertensive drugs. Although any antihypertensive agent could 
theoretically cause erectile dysfunction by decreasing the availability of blood to the 
corporal  arteries  (i.e.,  a  pressure-head  phenomenon),  differences  are  noted  between 
various  classes  of  medications,  with  less  erectile  dysfunction  associated  with 
angiotensin- converting enzyme inhibitors and selective beta-adrenergic blocking drugs 
(Grimm et  al.  1997;  Papatsoris  and Korantzopoulos 2006;  Shiri  et  al.  200628).  Non-
selective beta-adrenergic blocking drugs may cause erectile dysfunction by potentiating 
alpha-1 adrenergic  activity  in  the penis  as  well  as  by  a  possible  central  mechanism 
(Horowitz and Goble 197929). Thiazide diuretics have been reported to cause erectile 
dysfunction by an unknown mechanism (Chang et al. 199130). Spironolactone, acting as 
an anti-androgen, can cause a decrease in libido and gynecomastia as well as causing 
erectile dysfunction. Cimetidine, a histamine-H2 receptor antagonist, has been reported 
to decrease libido and cause erectile failure; it acts as an anti-androgen and can cause 
hyperprolactinemia (Wolfe 197931). Other drugs known to cause erectile dysfunction are 
estrogens and drugs with anti-androgenic action such as ketoconazole and cyproterone 
acetate.  In  many  disease  states,  the  associated  erectile  dysfunction  may  be  due  to 
multiple causes. About 50 percent of men with chronic diabetes mellitus are reported to 
have erectile dysfunction. In addition to the disease’s effect on small vessels, it may also 
affect the cavernous nerve terminals and endothelial cells, resulting in a deficiency of 
erectogenic neurotransmitter release. Additionally, in diabetics, corporal smooth muscle 
relaxation in response to neuronal- and endothelial-derived nitric oxide (NO) is impaired 
and may be secondary to the accumulation of glycosylation products (Saenz De Tejada32 
et  al.  1989;  Seftel  et  al.  1997;  Cartledge  et  al.  2001;  Angulo  et  al.  2003).  The 
pathophysiology of erectile dysfunction in DM is multifactorial, consisting of vascular, 
neurological,  endothelial,  and hormonal  insults.  The  penile  microvasculature  is  very 
sensitive to insults that affect other sites in the vascular system. DM is associated with 
atherosclerosis of both large and small penile vessels. Several studies point to corporal 
and pudendal arterial insufficiency as a common finding on both Doppler ultrasound and 
angiographic studies (Herman33 et al. 1978; Wang et al. 1993). DM affects a variety of 
nerve  fibers,  and  histologic  studies  in  animals  and  humans  have  demonstrated 
quantitative and qualitative changes in penile nerves (Faerman34 et al. 1974; Italiano et 
al. 1993; Morano 2003). On a cellular level, neurotransmitter abnormalities have been 
found in both human diabetics as well as in experimental animal models (Ehmke35 et al. 
1995; Vernet et al. 1995). In diabetics, corporal smooth muscle relaxation in response to 
neuronal- and endothelial-derived nitric oxide (NO) is impaired and may be due to the 
accumulation of glycosylation products (Saenz De Tejada et al. 1989; Seftel et al. 1997; 
Cartledge36 et al. 2001; Angulo et al. 2003). Although the data are somewhat conflicting, 
there may also be decreased production of NO (Ehmke et al. 1995). Additionally, animal 
and human studies have demonstrated hypogonadism in diabetics, which may contribute 
to both erectile dysfunction and decreased libido; however, this tends to be mild and 
likely does not play as great a role as the neuronal and vascular injuries (Murray37 et al. 
1987; Murray et al. 1992). Reduced libido may also be a significant etiology for ED in 
DM,  although  this  has  not  been  studied  in  conjunction  with  testosterone  levels 
(Nakanishi38 et  al.  2004).  Chronic  renal  failure  is  also  frequently  associated  with 
diminished erectile function, impaired libido, and infertility. The mechanism is probably 
multifactorial:  low  serum  testosterone  concentrations,  diabetes  mellitus,  vascular 
insufficiency,  multiple  medications,  autonomic  and  somatic  neuropathy,  and 
psychological stress. Men with angina, myocardial infarction, or heart failure may have 
erectile  dysfunction  from  anxiety,  depression,  or  concomitant  penile  arterial 
insufficiency. Social drugs including cigarettes and alcohol also affect erectile function. 
Cigarette  smoking  may  acutely  induce  vasoconstriction  and  penile  venous  leakage 
because of its contractile effect on the cavernous smooth muscle (Juenemann39 et al. 
1987);  more  importantly,  chronic  use  may  accelerate  atherosclerotic  changes  in  the 
penile microvasculature. Alcohol in small amounts may improve erections and increases 
libido because of its vasodilatory effect and the suppression of anxiety; however, large 
amounts can cause central sedation, decreased libido, and transient erectile dysfunction. 
Chronic alcoholism may cause hypogonadism and polyneuropathy, which may affect 
penile nerve function (Miller40 and Gold 1988). As physicians, we may cause erectile 
dysfunction through the medications we prescribe and the surgeries we perform. Pelvic 
surgeries,  particularly  radical  prostatectomies,  frequently  cause  erectile  dysfunction; 
analogous to diabetes mellitus, as described above, the erectile dysfunction may be the 
result  of  multiple  pathophysiologies  despite  one  underlying  insult.  Despite  surgical 
advances in preservation of the cavernous nerves (Walsh41 and Donker 1982), only 20% 
of patients return to pre-procedural erectile function a year after prostatectomy (Hu42 et 
al.  2004).  Even  in  nerve-sparing  procedures,  postoperative  neuropraxia  results  in  a 
cascade  of  events  including  loss  of  nocturnal  erections,  smooth  muscle  apoptosis, 
increased fibrosis, and eventual anatomic changes leading to venous leakage (Mulhall et 
al. 2002; Leungwattanakij et al. 2003; Iacono et al. 2005). Erectile dysfunction may be 
the  first  manifestation  of  many  diseases  including diabetes  mellitus,  coronary  artery 
disease,  hyperlipidemia,  hypertension,  spinal-cord compression,  pituitary tumors,  and 
pelvic  malignancies.  For  example,  a  recent  prevalence  study  found  that  men  with 
erectile  dysfunction  were  twice  as  likely  to  have  DM  and  concluded  that  erectile 
dysfunction may be used as an early marker for DM. This relationship was particularly 
strong in the younger age groups, in which the odds ratio of having DM was 3 (Sun31 et 
al.  2006).  Two  earlier  studies  found  that  11%  (Maatman32 et  al.  1987)  and  12% 
(Deutsch33 and  Sherman  1980)  of  impotent  men  were  found  to  have  previously 
undiagnosed DM. 
Definition:
Erectile dysfunction has been defined by the National Institute of Health (NIH) as 
the inability to achieve and/or maintain an erection for satisfactory sexual intercourse. 
Discordant  data  have  been  reported  on  erectile  dysfunction  epidemiology  with 
prevalence ranging from 12% to 52%. A recent study reported a prevalence of 12.8% in 
Italy (Foresta34 et al. 2005). French epidemiological studies estimate that the prevalence 
of erectile dysfunction is between 11% and 44%. Prevalence surveys show a correlation 
with age: the relative risk of erectile dysfunction increases by a factor of 2 to 4 between 
the ages of 40 and 70 years (Costa35 et al. 2005). 
Clinical Features:
Erectile dysfunction is a multi-factorial disorder and a common presentation for several 
systemic  illnesses,  particularly  vascular  occlusive  diseases  such  as  diabetes,  arterial 
hypertension, and atherosclerosis. Few patients consult their doctor, and only a small 
proportion of them receive treatment. Only few doctors take the initiative to discuss the 
question of their patients’ sex life (Costa et al.  2005). In fact,  the clinician must  be 
familiar with the pathophysiologic mechanisms of erectile dysfunction, its associations 
with  other  systemic  diseases,  the  indications  for  specialist  referral,  and  the  role  of 
specialized  testing  to  diagnose  and treat  this  disorder  effectively  (Lobo36 and  Nehra 
2005).  The  andrologist’s  cultural  baggage  must  include  the  ability  to  identify  the 
pathology that can determine erectile dysfunction and the capacity to program a specific 
diagnostic workup (Foresta et al. 2005). Demonstration of erectile disorders represents 
an excellent opportunity to conduct a general workup. In fact, management of erectile 
dysfunction is integral parts of preventive medicine since more than one-third of patients 
ignore their underlying health problem (Costa et al. 2005). 
Diagnosis of Erectile Dysfunction:
Baseline  diagnostic  evaluation  for  erectile  dysfunction  can  identify  the  underlying 
pathological conditions and associated risk factors in 80% of patients. Such screening 
may  diagnose  reversible  causes  of  erectile  dysfunction  and  also  unmasks  medical 
conditions that manifest with erectile dysfunction as the first symptom (Hatzichristou37 
et  al.  2002).  The  clinical  evaluation  of  patients  with  erectile  dysfunction  should  be 
thorough  and  systematic,  with  attention  to  the  appropriate  use  of  sexual  symptom 
questionnaires  and  symptom  scales,  detailed  medical  and  sexual  history,  physical 
examination, and basic screening laboratory tests. Still open is the question of which 
specific  tests  such  as  tumescence  and  rigidity  measurements,  intracavernous 
administration of vasoactive drugs and color/duplex Doppler sonography are required 
for adequate clinical assessment. 
Preliminary Clinical Assessment:
Prior  to  instrumental  or  invasive  procedures,  patient  reported  assessment  should  be 
performed. Patient self report, administered questionnaires, event logs or simple patient 
diaries are commonly used for the diagnosis of erectile dysfunction (Rosen et al. 2006). 
The International Index of Erectile Function (IIEF) questionnaire can be used to measure 
the erectile function (Rosen et al. 1997). It simplifies the preliminary assessment and can 
help  to  evaluate  and  define  the  cause  of  the  erectile  dysfunction  and  identify  the 
underlying vascular issue. Even though the IIEF questionnaire was originally proposed 
to evaluate the results of treatments, it can also be used in clinical practice to evaluate 
the erectile function in all patients attending ultrasound investigation. The questionnaire 
has been shown to be highly versatile and can be employed in all patients with erectile 
dysfunction regardless of the cause, co-morbidities and cultural background. 
A simplified and reduced version has been developed called the Sexual Health 
Inventory for Men (SHIM), and is used in clinical practice as a valid method to evaluate 
the severity of erectile dysfunction (Rosen et al. 2002). The SHIM score also allows the 
efficacy of treatment to be monitored. These two indices give a global evaluation of 
erectile  function,  but  do not  assess other  sexual  disorders  since they do not  provide 
information  regarding  the  causes  of  erectile  dysfunction,  which  can  be  organic  or 
psychological  or  secondary  to  other  health  issues  (diabetes,  cardiovascular  disease, 
drugs,  neurological  disease,  etc.).  Another  important  issue in the initial  medical  and 
sexual history of the patient regards the erection hardness, which is fundamentally key to 
erectile  function.  An  Evaluation  Hardness  Grading  Scale  (EHGS)  can  be  used, 
consisting of a self reported measure that classifies erection hardness on a four-point 
scale (Mulhall et al. 2006). This evaluation is very simple and quick to perform and 
gives important clinical information of patient satisfaction of his erectile function.
Sexual Health Inventory for Men (SHIM)
SCORES 1 2 3 4 5 
How  do  you  rate  your 
confidence  that  you  could 
get &  keep an erection? 
very low low moderate high very high
How  often  were  your 
erections  hard  enough for 
penetration? 
never  or 
almost 
never 








How often were you able to 
maintain  your  erection 
after  you  had  penetrated 
(entered) your partner? 
never  or 
almost 
never 








How  difficult  was  it  to 
maintain  your  erection  to 









How  often  was  it 
satisfactory for you? 
never  or 
almost 
never 








Erection Hardness Grading Scale (EHGS)
Grade 1: Increase in size of penis, but not hardness (rigidity) 
Grade 2: Increase in size and slight increase in hardness (rigidity), but insufficient for 
sexual intercourse
Grade 3: Increase in hardness (rigidity), sufficient for sexual intercourse, but not fully 
hard (rigid)
Grade 4: Fully hard rigid erection
Ultrasound Imaging Findings in Erectile Dysfunction
Several  changes  are  detected  in  patients  with erectile  dysfunction  that  are  useful  to 
differentiate  among  different  underlying  causes  for  this  condition.  In  particular, 
anatomical and vascular alterations can be evaluated at grey-scale and color Doppler 
ultrasound, as well  as pathological spectral changes in the cavernosal arteries and in 
other penile vessels. 
Grey-Scale Ultrasound Findings:
The morphological aspects to define with grey-scale ultrasonography are the presence of 
calcifications and kinking of the cavernosal arteries; diameter and size changes of the 
cavernosal arteries before and after pharmacological injection; distension and texture of 
the erectile tissue evaluated before and during erection. In older patients, and in those 
suffering from diabetes or chronic renal failure, micro calcifications in the wall of the 
cavernosal arteries are frequently detectable and are the expression of calcium deposits 
in atheromatous endothelial plaques or in the tunica media as observed in subjects on 
chronic hemodialysis. Measurement of the diameter changes in the cavernosal arteries 
after drug injection is clinically more useful since it expresses the stiffness of the arterial 
wall. In normal subjects there is normally a 75 to 120% increase in size of the vessels 
whose  diameter  is  of  0.5–0.7  mm  at  rest  and  1–1.2  mm  after  stimulation.  This 
measurement is performed using the maximum electronic magnification of the scanner 
to  reduce  errors  due to  incorrect  positioning of  the  electronic  calipers  (Chiou et  al. 
1999). The size increase of the arteries in patients with arteriogenic ED is usually less 
than 75%. The functional response of the vessels to the drug is nonspecific and not 
always expression of stenosis or obstruction, but can be secondary to a reduced elasticity 
or contraction of the muscular wall. A normal vascular response is considered when the 
increase in size is of 100% or more with respect to the basal values. The measurement of 
the diameter changes of the corpora cavernosa during the different phases of erection is 
another  parameter  that has been used.  The distension can be asymmetric because of 
reduced  relaxation  of  the  cavernosal  tissue  on  one  site  due  to  structural  changes 
(fibrosis)  or  secondary  to  unilateral  reduced  flow  because  of  unilateral  arterial 
obstruction. The measurement of the area of the corpora cavernosa in the transversal 
scan is simple using the electronic facilities of the ultrasound equipment. It is possible to 
calculate  immediately  the  area  delimitated  with  the  trackball.  Actually  these 
measurements are rarely used in the clinical practice because penile changes in size and 
rigidity are well evaluated clinically and manually (Nelson and Lue 1989).
Color Doppler Imaging:
Color  imaging  is  fundamental  to  identify  the  cavernosal  arteries  and  to  detect  the 
presence and direction of  flow, especially  in patients  with reduced distension of the 
vessel  after  drug stimulation (Mancini  et  al.  2000). The vessel  kinking, stenosis and 
obstruction are easily identified. Obstructions appear as non-colored segments of the 
arteries, while stenoses are associated with areas of increased velocity and post-stenotic 
turbulence. Color Doppler imaging is useful to detect flow in the cavernoso-dorsal and 
cavernoso-urethral anastomoses, which are common in patients with arteriogenic erectile 
dysfunction. Because of extensive arterial  lesions, the flow in the helicine arteries is 
reduced,  and  sometimes  the  distal  part  of  the  cavernosal  arteries  is  not  visualized 
because of reduced flow velocity (Sarteschi et al. 1998). Power Doppler imaging and the 
3D  rendering  techniques  are  proposed  to  detect  the  arterial  wall  lesions  and  the 
distribution  of  the  elicine  arteries  in  subjects  with  diffuse  lesions  of  the  small 
intracorporeal  vessels  as  observed in  diabetics  (Montorsi  et  al.  1998;  Klingler  et  al. 
1999).  In  patients  with venous  occlusive  erectile  dysfunction  the cavernosal  flow is 
elevated  and  easily  detected.  The  vessels  show  an  increased  diameter  and  can  be 
followed  for  a  long  course  in  the  center  of  the  corpus  cavernosum.  The  helicine 
arterioles are numerous and visible up to the tunica albuginea (Hampson et al. 1992). 
Venous leakage pathways are patent.
Spectral Doppler Imaging:
Spectral analysis is the most important parameter used to characterize the severity and 
the nature of the erectile dysfunction (Knispel and Andresen 1992). It  is possible to 
calculate  semi  quantitatively  the  penile  perfusion  and  indirectly  to  calculate  the 
intracorporal  pressure,  which  are  the  main  factors  that  influence  the  validity  and 
duration of the erection (Shabsigh et al. 1989). There is a general agreement that the 
peak systolic velocity (PSV) measured at the level of the peno-scrotal junction is the 
best parameter for a clinical judgment of the arterial perfusion (Oates et al. 1995). PSV 
above 35 cm/s is considered the expression of a normally functioning arterial tree, even 
though arteriography can detect atheromatous parietal lesions that are hemodynamically 
non-significant. When the Doppler examination reveals a PSV less than 25 cm/s, the 
erectile dysfunction is considered of arteriogenic origin with a sensitivity of about 100% 
and a specificity of 95% as shown by the arteriographic studies that correlated flow data 
with  arteriographic  images  (Valji  and Bookstein  1993).  Much  more  complex  is  the 
clinical  evaluation of patients who show PSV values between 25 and 35 cm/s.  This 
range of values is commonly observed in older subjects with mild erectile dysfunction. 
Probably they have a stiffness of the arterial walls with intimal thickening and reduced 
response  to  PGE1  stimulation,  secondary  to  an  endothelial  lesion  and  reduced  NO 
production. In these patients stenosis or obstruction of the precavernosal arteries can be 
suspected and the flow study of these larger vessels should be performed. The terminal 
branches of the internal pudendal artery can be explored with a high linear frequency 
probe positioned in the perineal area under the scrotum. The flow detected at the level of 
the cavernosal arteries can be asymmetric, and when the difference of PSV is greater 
than 10 cm/s a unilateral arterial insufficiency must be suspected with secondary flow 
impairment. When the arterial obstruction is complete, color Doppler imaging can show 
flow  inversion  in  the  cavernosal  artery,  easily  detected  in  the  longitudinal  and 
transversal scans because of the different color of flow. At spectral analysis the flow is 
reversed in the proximal portion of the artery and normally directed in the distal part. 
The curve obtained is of low amplitude with increased time to peak. The blood flows 
from  the  contralateral  patent  cavernous  artery  or  from  the  dorsal  artery  through 
transeptal or dorso-cavernosal anastomoses (Wegner et al. 1995). Cavernosal-spongiosal 
communications with reversed flow can refill the cavernosal artery retrogradely as well. 
Spectral curve in patients with arteriogenic erectile dysfunction is characterized by the 
absence of typical phase variations that can be observed in normal subjects. The flow is 
reduced and unchanged during the whole scanning time. Valid erections can sometimes 
be observed in patients with extensive arteriogenic lesions and PSV below 25 cm/s, but 
with a preserved and active veno-occlusive mechanism that compensates for the reduced 
arterial  inflow.  In  these  cases  the  beginning  of  the  erection  is  delayed,  but  can 
sometimes be long standing. Veno-occlusive erectile dysfunction is more common in 
clinical practice and is usually observed in younger patients without arterial disease. As 
confirmed by cavernosography and cavernosomanometry (Kropman et  al.  1992),  the 
diagnosis is made on the basis of a high and persistent peak systolic velocity, which is 
superior to the cut-off values of 35 cm/s, and end diastolic velocity with a sensitivity of 
90–94%. The disappearance or inversion of the diastolic flow is indicative of a correctly 
functioning  veno-occlusive  mechanism,  and  the  erectile  dysfunction  is  probably  of 
different origin (hormonal, psychological) (Wespes et al. 1998). The use of the resistive 
index (RI) to measure the venous function does not show advantages over the simple 
end diastolic velocity values. RIs of 0.9–1.0 are indicative of normality, while lower 
values suggest  venous leakage.  When the RI is  below 0.75 end diastolic velocity  is 
generally higher than 10–12 cm/s in 95% of patients. In these cases the venous leakage 
is persistent and elevated, and there is no efficacy of oral drugs. The presence of an 
elevated end diastolic velocity is indicative of low intracavernosal pressure, inadequate 
to obtain and maintain rigidity sufficient for normal intercourse (de Meyer and Thibo 
1998).  Less  frequently  observed  are  cases  of  erectile  dysfunction  of  mixed  origin, 
arteriogenic and venous, showing low systolic velocity and persistent diastolic flow. The 
response  to  pharmacological  stimulation  in  the  dorsal  penile  arteries  is  completely 
different from in the cavernosal. They do not show the typical phase changes detected in 
the cavernosal arteries and secondary to the intracorporeal pressure (Hwang et al. 1991). 
The flow is elevated even in full rigidity. They provide blood to the glans, and the peak 
systolic  velocity  increases  to  produce an engorgement  of  the glans vasculature  with 
secondary distension and stiffness of this part of the penis. Lesions of these vessels can 
be the cause of reduced tumescence of the glans and of a “soft-tip” during erection. In 
the deep dorsal vein the flow is always high during all the phases of erection. Commonly 
it increases after drug injection. The flow velocity measurement is not clinically useful 
in patients with erectile dysfunction and particularly in those with venous leakage (Virag 
and Sussman 1998). 
Dorsal-cavernosal  anastomosis  is  commonly  detected  in  patients  after 
pharmacologically  induced  erection,  independently  of  the  nature  of  the  erectile 
dysfunction. The flow direction is normally from the dorsal artery to the cavernosal and 
the  end  diastolic  velocity  is  always  high  and  not  influenced  by  the  intracorporeal 
pressure.
Materials and method:
Seventy  seven  consecutive  patients  referred  from various  departments  like  urology, 
diabetology, psychiatry and general medical out patient departments were included in 
the study. All patients had the complaint at least 6 months of erectile dysfunction.
All  patients  had  a  detailed  clinical  history  and  basic  blood  chemistry  done. 
Standard questionnaire (Sexual health inventory for men - SHIM) was used to clinically 
grade the amount of erectile dysfunction. Those subjects with scores less than 21 were 
included in the study.
The sequence of the study module is as follows:
• All patients to undergo penile Doppler with Inj.Papaverine of standard dose (1mg)
• After  one  week  interval  all  patients  again  to  undergo  penile  Doppler  with 
Tab.Sildenafil 
• During  penile  Doppler  examination  both  hemodynamic  changes  (by  colour 
Doppler and spectral pattern) and clinical assessment were done simultaneously.
• Clinical  grading  is  done  using  Erection  Hardness  Grading  Scale  (EHGS) 
introduced by Mulhall et al. 2006 
Inclusion criteria:
• Subjects with clinically diagnosed erectile dysfunction 
• SHIM score less than 21
Exclusion criteria:
• Patients on nitrates 
• Congestive cardiac failure 








• Venous leak 
Observation:




















Age range of total number of subjects was from 22 to 65 years with a mean age of 44. 
According to the SHIM questionnaire the average score of the 77 subjects was 14.6.
Etiology:
Though in vast majority of cases diabetes and hypertension was the causative factor, 
around 30% of subjects did not have any known risk factors.
Response:
Out of  77  subjects  59 were  responding normal  to  Papaverine(  Psv  more  than 
30cm/sec)  and 56 to  Sildenafil.  Papaverine  identified  18  subjects  as  having erectile 




Using Erection Hardness Grading scale(EHGS) the following number of subjects 
were categorized into 4 grades as follows:
               PAPAVERINE                 SILDENAFIL
GRADE 0 18 20
GRADE 1 3 18
GRADE 2 25 31
GRADE 3 31 8
Clinical grading:
Side effects:
Priapism is a known side effect of Papaverine which occurred in 4 subjects in our series. 
And out of this four 2 needed a surgical management. Sildenafil produced no incidence 




















• Positive predictive value:95%
• Negative predictive value:75% 
Discussion
Normal Doppler study (as defined by attaining a PSV of more than 30 cm per sec 
and no diastolic flow and no visible venous leak) were obtained in 77% of subjects with 
Papaverine and 73% of patients  with Sildenafil.  The difference in  the proportion of 
subjects responding normally among theses two drugs was 3%. This small difference 
was proven statistically insignificant. So the number of normal responders to both of 
theses drugs was derived to be equal. Thus Sildenafil gets a sensitivity of 91% taking 
Papaverine as gold standard.
There were 4 cases of erectile dysfunction due to venous insufficiency when done 
with Papaverine.  But  all  these 4 cases  were identified by  Sildenafil  as  only  arterial 
pattern of insufficiency. Though Sildenafil has got a good sensitivity the fact that it has 
poor  capacity  to  discriminate  between  arterial  and  venous  pattern  of  insufficiency 
reduces ones diagnostic confidence. The following is one such example:
With Papaverine:
 With sildenafil:
Comparison with previous study:
Comparing the previous study by copel et al our study has a larger number of sample 
volume and thus more reliable in a statistical aspect. Other important difference is that 
the previous study used audio visual stimulation where as our study had incorporated 
self  tactile  stimulation as  an adjunct  to Sildenafil.  Using self  tactile  stimulation was 
comfortable  to  most  of  the  patients.  Percentage  of  subjects  responded  normally  to 
Sildenafil  was very low compared to that with Papaverine in their study. But in our 
study the proportions were proven to be statistically equivalent.
Considering  clinical  grading  of  erection  by  erection  hardness  grading  scale 
(EHGS),  very  good  grades  of  erection  (grade  4)  was  obtained  in  31  subjects  with 
Papaverine and in only 8 patients with Sildenafil. The difference in this proportion is 
statistically  significant  enough  to  say  the  very  good clinical  grades  of  erection  was 
achieved in more subjects when Papaverine is used, comparing to Sildenafil. 
Comparison with previous study
Study by Copel et al Our study 
Nature of stimulus used Audio visual Self tactile 
No of pts attaining 
normal PSV by 
sildenafil 
46% 73% 
No of pts attaining 
normal PSV by 
Papaverine 
77% 77% 
Statistical difference Significantly different Statistically equivalent 
There  are  few  limitations  in  this  study.  The  sample  subjects  are  those  with 
complaints of erectile dysfunction owing to various causes we enumerated previously. 
Each specific cause is a separate disease entity which is expected to respond in different 
ways to one or both of these drugs. We could have avoided this only if we had selected a 
homogenous group of people with erectile dysfunction with a same etiology. There is 
also no control group. The type of the study is such that we can not have a normal 
people with out erectile dysfunction to undergo injection of Papaverine and ingestion of 
Tab.Sildenafil. 
Painful priapism is the well known complication of Papaverine. In our series 4 
cases of priapism occurred with Papaverine out of which 2 needed surgical management. 
One  went  well  with  vacuum aspiration  and  other  with  cavernosa  spongeosal  shunt. 
Sildenafil  produced no case of priapism among these 77 subjects.  Leaving priapism, 
other complications like sweating, hypotension and nausea were not so frequent with 
both of these drugs.




The study becomes unique in that this is the first one of its kind where tab .sildenafil is 
compared with Inj.Papverine in doing penile Doppler using self tactile stimulation as an 
adjunct. Another originality of this study is the large number of sample subjects ever 
used  which  has  helped  to  avoid  statistical  bias.  The  study  revealed  that  there  is 
significant increase in the blood flow of penile vasculature with Tab.Sildenafil, and it 
could be used as an erectogenic drug in performing penile Doppler when combined with 
self tactile stimulation. The following facts were derived by analyzing the results:
• Though the proportion of persons getting very good a clinical grade of erection 
with  Sildenafil  is  significantly  low  when  compared  to  Inj.Papaverine,  the 
sensitivity is more than 90%. 
• Drawback with Sildenafil is that it fails to differentiate when arterial and venous 
pattern  of  insufficiency  as  a  cause  of  erectile  dysfunction.  All  patients  with 
erectile dysfunction due to venous insufficiency with Papaverine were identified 
as arterial insufficiency with Sildenafil in our study.
• With  the  given  sensitivity,  good  patient  compliance  and  lower  side  effects 
Sildenafil can be preferred over Inj.Papaverine in doing penile Doppler to screen a 
subject for erectile dysfunction.
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Duration of symptoms: 
Relevant clinical history: 
• Possible etiological factors
• Associated co morbidities
• Drugs intake
Basic blood investigations: 




B mode USG findings:
Doppler: 
Papaverine 







Time PSV EDV Venous leak Interpretation Clinical grading
45 min 
60 min 
90 min
120 min
150 min 
Side effects:
